Carisma Therapeutics (CARM)
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its...
- Open
- 0.0007
- High
- 0.0007
- Low
- 0.0007
- Prev. Close
- 0.0009
- Volume
- 992
- Turnover
- 0.69
- Avg Price
- 0.0007
- Bid/Ask Ratio
- --
- Amplitude
- 0.00%
- 52wk High
- 0.4400
- Volume Ratio
- 0.08
- Turnover Ratio
- 0.00%
Carisma Therapeutics Analyst Rating
View moreForecast & Rating
Nov 7, 2025Price forecast
$1.00142757.14%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · May 26 at 04:05 AM
Positive Report for Carmila SAS (CARM) from Jefferies
- StockTitan · May 11 at 08:15 AM
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels | CAI Stock News
- Tip Ranks · Apr 8 at 07:40 AM
Carasent Sets 14 April Date for Q1 2026 Results and Webcast
- Tip Ranks · Mar 29 at 11:19 PM
Carma issues new shares under employee incentive plan and confirms compliance
- Pharmaceutical Technology · Mar 6 at 10:11 AM
Liberate Bio gains licences for myeloid-specific CAR design patents
- Tip Ranks · Mar 4 at 01:59 AM
Carma Director Owen Wilson Lifts Stake with On-Market Share Purchases
